SGLT2 Inhibitor

5 Drugs classified under this drug class

SGLT2 Inhibitor. Dapagliflozin (propanediol monohydrate) 5 mg, 10 mg.
F.C. TAB.: 7, 14, 28, 30, 90, 98.
Monother., add-on comb. ther.: 10
mg×1/d for monother., add-on comb.
ther. with other glucose-low. med. prod.
include. insulin. Pts. with severe hep.
imair. init. recom. dose is 5 mg. If well
tolerated, the dose may be incr. to 10
mg.
Indic. In adults aged 18 yrs., older with
type 2 diabetes mell. to improve
glycaemic control as: Monother.: when
diet and exercise alone do not provide
adequate glycaemic control in pts. for
whom use of metformin is considered
inappropriate due to intolerance. Add-on
comb. ther.: In comb. with other glucoselow.
med. products includ. insulin, when these,
together with diet and exercise, do not
provide adequate glycaemic control.
C/I: Hypersens.

DPP-4 Inhibitor, SGLT2 Inhibitor. Empagliflozin 10, 25 mg, Linagliptin 5 mg.
F.C.TABS.: 30. The recomm. dose of this drug is 10 mg empagliflozin/5 mg linagliptin once dly. in the morn., taken with/ without food. In pts. tolerat. this formul., the dose may be incr. to 25 mg empagliflozin/5 mg linagliptin once dly. See lit.
Indic. as an adjunct to diet and exercise to improve glycem. control in adults with type 2 diab. mell. when tmt. with both empagliflozin and linagliptin is approp..
C/I: Sev. ren. impair., end-stage renal dis., or dialysis. Hist. of hypersens. reaction to linagliptin, such as anaphylax., angioedema, exfoliative skin condit., urticaria, or bronch. hyperreactivity. Hist. of serious hypersens. reaction to empagliflozin.

SGLT2 Inhibitor. Empagliflozin 10 mg, 25 mg.
F.C. TABS.: 30×10, 25 mg. In pts. with volume depletion, correct. this condition prior to init. of empagliflozin is recomm.
Recomm. dose for all indic. is 10 mg orally daily.
- For addit. glycemic ctrol., incr.to 25 mg in pts. tolerating 10 mg dly.
- Use for glycemic control is not recomm. in pts. with eGFR less than 30 mL/min/1.73 m². See lit.
 Products 10 and 25 mg indic.:
as an adjunct to diet and exercise to improve glyc. ctrol. in adlts. with type 2 diabetes mell.
to red. the risk of CV death in adlt pts. with type 2 diabetes mell. and established CV dis.
10 mg indic.:
•to red. the risk of CV death and hosp. for HF in adlts with HF.
•to red. the risk of sust. decline in eGFR, end-stage kidney dis., CV death, and hosp. in adlts with chron. kidney dis. at risk of progr.
as an adjunct to diet and exercise to improve glyc. ctrol. in ped. ptts. aged 10 years and older with type 2 diabetes mell.
C/I: Hypersens., angioedema react. occurred.

Biguanide, SGLT2 Inhibitor. Empagliflozin 5 mg, 12.5 mg, Metformin Hydrochloride 500, 850, 1000 mg.
F.C. TABS.: 14, 60, 180. In pts. with volume depletion not prev. treated with empagliflozin, correct this condit. before init. Adjust dosing based on effectiveness and tolerab. while not exceed. the max. recom. dly. dose of metformin HCl 2000 mg and empagliflozin 25 mg.
Twice dly. with meals; with gradual dose escalat. to reduce the GI side effect. due to metformin. See lit.
Indic. in adult. aged 18 yrs. and older with type 2 diab. mell. as an adjunct to diet and exercise to improve glycaemic control in pts. inadequat. control. on their maxim. tolerat. dose of metformin alone. In pts. inadequat. control. with metformin in comb. with other glucose-low. med. products, includ. insulin. In pts. already being treated with the comb. of empagliflozin and metformin as separate tabs.
C/I: Pts. with Moder.- sev. renal impair. (eGFR less than 45 mL/min/1.73 m2), end stage renal dis., or dial. Acute /chron. metabol. acidosis, includ. diabet. ketoacidosis. Diabet. ketoacidosis should be treated with insulin. His. of serious hypersens. react. to empagliflozin or metformin.

Biguanide, SGLT2 Inhibitor. Dapagliflozin 5 mg, 10 mg, Metformin Hydrochloride 500 mg, 1000 mg.
E.R. TABS.: 56× 5/1000mg, 28×10/1000mg. Dosing may be adjust. based on effective. and tolerab. while not exceed. the max. recomm. dly. dose of 10 mg dapagliflozin and 2000 mg metformin HCl. Pts. taking an eve. dose of metformin XR should skip their last dose before the init. of the therap.
The drug should be taken once dly. in the morn. with food with gradual dose escalat. to reduce the GI side effects due to metformin.
Tabs. must be swallow. whole and never crushed, cut, or chewed.
In pts. with volume depletion, correct. this condit. prior to initiat. of this drug.
Indicated as an adjunct to diet and exercise to improve glycem. control in adults with type 2 diabetes mell. when tmt. with both dapagliflozin and metformin is appropriate.
C/I: Moder.-sev. renal impair. (e.g., serum creatinine levels ≥1.5 mg/dL for men, ≥1.4 mg/dL for women, or eGFR<60 mL/min/1.73m² or CrCl<60 mL/min), which may also result from conditions such as cardiovasc. collapse (shock), acute MI, and septicemia.
History of a serious hypersens. reaction to dapagliflozin or hypersens. to metformin HCl.
Acute/chron. metabolic acidosis, include.  diabetic ketoacidosis, with/without coma. Diabetic ketoacidosis should be treated with insulin.